

## Interactions of Antiviral Indolo[2,3-*b*]quinoxaline Derivatives with DNA

L. Marcus Wilhelmsson,<sup>†</sup> Ngarita Kingi,<sup>‡,§</sup> and Jan Bergman<sup>\*,‡</sup>

Department of Chemical and Biological Engineering/Physical Chemistry, Chalmers University of Technology, SE-41296 Gothenburg, Sweden, Unit for Organic Chemistry, Department of Biosciences and Nutrition, Karolinska Institute, SE-14157, Huddinge, Sweden, and Drug Development, Vironova AB, Smedjegatan 6, SE-13134 Nacka, Sweden


Received June 30, 2008

Here, we present the synthesis of five novel indoloquinoxaline derivatives and investigate the DNA binding properties of these monomeric as well as dimeric compounds using absorption, fluorescence, and linear dichroism. Several of the mono- and dicationic derivatives presented have previously demonstrated an excellent antiviral effect that is higher than already acknowledged agents against human cytomegalovirus (CMV), herpes simplex virus type 1 (HSV-1), and varicella-zoster virus (VZV). We find that the DNA binding constants of the monomeric and dimeric derivatives are high ( $\sim 10^6$ ) and very high ( $\sim 10^9$ ), respectively. Results from the spectroscopic measurements show that the planar aromatic indoloquinoxaline moieties upon interaction with DNA intercalate between the nucleobases. Furthermore, we use poly(dA-dT)<sub>2</sub> and calf thymus DNA in a competitive binding experiment to show that all our derivatives have an AT-region preference. The findings are important in the understanding of the antiviral effect of these derivatives and give invaluable information for the future optimization of the DNA binding properties of this kind of drugs.

### Introduction

The indole alkaloid ellipticine (**1** in Figure 1), first isolated in 1959 by Goodwin et al.<sup>1</sup> from *Ochrosia elliptica*, appeared to display anticancer activity, and within the next two decades, intense research in both the synthetic and biological areas of ellipticine and its analogues produced commercial cancer chemotherapy agents such as celiptium.<sup>2</sup> Unfortunately, problems with the toxicity of these agents have more or less limited the success of these drugs in the pharmaceutical market.

Nevertheless research continued with the indolo[2,3-*b*]quinoxaline system (i.e., **2** in Figure 1) as analogues to the cytotoxic agent ellipticine. The replacement of the methyl groups in positions 5 and 11 by nitrogen atoms gave little or no cytotoxicity against most cancer models except for Burkitt's lymphoma, a cancer type that is closely related to viral activity.<sup>3</sup> This information resulted in the development of 2,3-dimethyl-6(2-dimethylaminoethyl)6*H*-indolo-(2,3-*b*)quinoxaline (B-220)<sup>4</sup> (**3** in Figure 1), and further studies revealed that it exhibited good antiviral activity against herpes simplex virus type 1 (HSV-1), cytomegalovirus (CMV), and varicella-zoster virus (VZV). It has been reported that the mechanism of the antiviral action against HSV-1 appears to involve binding by intercalation into the DNA helix and, thus, disturbing the processes that are vital



**Figure 1.** The alkaloid ellipticine, **1**, the indolo[2,3-*b*]quinoxaline system, **2**, and the parent compound of the indoloquinoxaline derivatives used in this study: 2,3-dimethyl-6(2-dimethylaminoethyl)6*H*-indolo-(2,3-*b*)quinoxaline (B-220), **3**.

for viral uncoating.<sup>5,6</sup> Further development of a new series of indoloquinoxaline derivatives related to B-220 have shown to have a significant effect against autoimmune inflammatory diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA), and other diseases.<sup>7</sup>

To improve DNA-binding of the family of ellipticine analogues and to optimize their antiviral effect, we have synthesized a series of novel indoloquinoxaline derivatives (**4–8** in Figure 2). In this optimization of the drugs, we have varied parameters that from previous studies are well known to be important for DNA binding, e.g., the number of positive charges,<sup>8–11</sup> the number of interacting units (comparison between monomeric or dimeric compounds),<sup>12–32</sup> and the hydrophobicity of the interacting unit (see for example Karlsson et al.<sup>33</sup>). The quaternary mono- or dicationic agents (**6–8** in Figure 2) developed using the structurally related **1–3** as parent compounds have indeed been shown to have excellent inhibitory effects against human CMV (HCMV), HSV-1, and VZV. Modified inhibitory tests of antiviral activity against HCMV were compared with already acknowledged antiviral agents ganciclovir, phosphonomethanoic acid, and the B-220 compound. This comparison indicated 100% inhibition by the novel compounds compared to 30, 50, and 20% inhibition of the acknowledged antiviral agents, respectively. These preliminary results are not conclusive as to what the underlying antiviral


\* To whom correspondence should be addressed. Tel: +46 (0)8 608 9204. Fax: +46 (0)8 608 15 01. E-mail: jan.bergman@biosci.ki.se.

<sup>†</sup> Chalmers University of Technology.

<sup>‡</sup> Karolinska Institute.

<sup>§</sup> Vironova AB.

<sup>a</sup> Abbreviations: 11,11'-bidppz, 11,11'-bis(dipyrido[3,2-*a*:2',3'-*c*]phenazine); B-220, 2,3 dimethyl-6(2-dimethylaminoethyl)6*H*-indolo-(2,3-*b*)quinoxaline (by Bergman- the 220<sup>th</sup> synthesis in this project); C4(cpdppz)2, *N,N'* bis(cpdppz)-1,4-diaminobutane; CMV, cytomegalovirus; cpdppz, 12-cyano-12,13-dihydro-11*H*-8-cyclopenta[*b*]dipyrido[3,2-*h*:2',3'-*j*]phenazine-12-carbonyl; ct-DNA, calf thymus DNA; HCMV, human cytomegalovirus; HSV-1, herpes simplex type 1; LD, linear dichroism; LD', reduced linear dichroism; MQ-water, MilliQ water; MS, multiple sclerosis; phen, 1,10-phenanthroline; poly(dA-dT)<sub>2</sub>, duplex of two alternating adenine-thymine polynucleotides; RA, rheumatoid arthritis; SAR, structure-activity relationship; SDS, sodium dodecyl sulfate; VZV, varicella-zoster virus; YO, oxazole yellow; YOYO, homodimeric derivative of oxazole yellow (YO).



**Figure 2.** Novel monomeric and dimeric indoloquinoxaline derivatives synthesized and used in this study: compounds **4**, 2,3-dimethyl-6-(2-dimethylaminoethyl)-6*H*-indolo[2,3-*b*]quinoxaline hydrochloride; **5**, 9-amino-2,3-dimethyl-6-(2-dimethylaminoethyl)-6*H*-indolo[2,3-*b*]quinoxaline hydrochloride; **6**, 2,3-dimethyl-6-[2-(trimethylamino)ethyl]-6*H*-indolo[2,3-*b*]quinoxaline iodide; **7**, bis-indolo-(2,3-*b*)quinoxaline-6*H*-(3,3;10,10-tetramethyl)-3,10-di-(3,10)-azadodecane bromide; and **8**, bis-indolo-(2,3-*b*)quinoxaline-6*H*-(3,3;7,7-tetramethyl)-3,10-di-(3,7)-azaheptane bromide.

mechanism is, although it appears to involve the impairment of the tegument protein that binds to the viral capsid. The novel compounds did not show any toxicity as assayed by propidium iodide staining of cell cultures of infected and uninfected human lung fibroblasts.<sup>34</sup> Obviously, further tests were considered necessary to comprehend the surprisingly different viral inhibition results especially exhibited between the novel compounds and B-220.

Here, we perform extensive spectroscopic studies to investigate the interaction between the novel indoloquinoxaline derivatives (**4–8**) and DNA by determining the binding constant, the binding geometry, and the AT-specificity. The variation in the structure, such as in the linker length and its position, the permanent/nonpermanent quaternary nitrogen salt and the introduction of new substituent groups on the indoloquinoxaline moiety, are shown to have an immediate significant influence on the interaction between the ligands and DNA. These structure–activity relationships (SAR) give important understanding in the optimization of the antiviral effects of these promising drugs.


## Results and Discussion

Table 1 shows the wavelength of maximum absorption of the low energy band and the corresponding extinction coefficient of the indoloquinoxaline derivatives (**4–8**) measured in MQ-water. Furthermore, the appearance of the lowest energy part of the absorption spectra of the indoloquinoxaline derivatives can be seen as the solid lines in Figure 3. The extinction coefficients are all reasonably similar, ranging from 15000 to

**Table 1.** Extinction Coefficients of the Indoloquinoxaline Derivatives (**4–8**) Measured in MQ-Water at Room Temperature

drug	$\lambda_{\text{max}}$ (nm)	$\epsilon$ ( $M^{-1} \text{ cm}^{-1}$ )
<b>4</b>	363	17500
<b>5</b>	374	15000
<b>6</b>	363	19000
<b>7</b>	345	21500
<b>8</b>	345	21000

21500  $M^{-1} \text{ cm}^{-1}$ . The low energy absorption maxima range from 345 to 374 nm with the monomers at slightly longer wavelengths (363–374 nm) than the dimers (345 nm). It is worth noting that the monomers containing exactly the same chromophoric units, **4** and **6**, as expected have very similar wavelength maxima and extinction coefficients. The slightly lower extinction coefficient and absorption at longer wavelengths for monomer **5** compared to those of **4** and **6** can be explained by the addition of the amino-group in the 9-position of the indoloquinoxaline system. Also, it is worth noting that the extinction coefficients and wavelength maxima for **4–6** show



**Figure 3.** Absorption spectra of (a) **4**, (b) **5**, (c) **6**, (d) **7**, and (e) **8** in the presence (dashed lines) and absence (solid lines) of calf thymus DNA. Concentration of calf thymus DNA is 160  $\mu\text{M}$  ([base]) and those of the monomeric and dimeric indoloquinoxaline derivatives 10 and 5  $\mu\text{M}$ , respectively. Measurements performed at room temperature in a 10 mM phosphate buffer, pH 7.5 (total  $\text{Na}^+$ -concentration 100 mM).

**Table 2.** Equilibrium Constants of the Indoloquinoxaline Derivatives (4–8) Binding to poly(dA-dT)<sub>2</sub> and Ratio in Binding Constants between poly(dA-dT)<sub>2</sub> and Calf Thymus DNA in a Competitive Binding Experiment<sup>a</sup>

drug	$K_{AT}$	$K_{AT}/K_{ct-DNA}$
4	$10^5$ – $10^6$	1.8
5	$10^6$ – $10^7$ <sup>b</sup>	1.7
6	$10^6$ – $10^7$	2.4
7	$10^8$ – $10^9$	3.0
8	$10^8$ – $10^9$ <sup>c</sup>	1.9


<sup>a</sup> Measurements were performed at 22°C in a 10 mM phosphate buffer, pH 7.5 (total  $\text{Na}^+$ -concentration 100 mM). <sup>b</sup> Because of the lack of fluorescence of 5, its equilibrium constant of DNA binding was estimated in a competitive binding experiment with 6. <sup>c</sup> The equilibrium constant of DNA binding of 8 was calculated using a binding site size of 3 base pairs (for the other dimer, 7, a site size of 4 was used).

great resemblance to previously reported values for molecules built from the same kind of chromophore, even though those measurements were performed in ethyl acetate.<sup>35</sup> As expected, also dimers 7 and 8 containing the same chromophoric unit have very similar wavelength maxima and extinction coefficients. The fact that 7 and 8, which have two chromophoric units that are essentially identical to monomers 4 and 6, do not exhibit a 2-fold increase in the extinction coefficient can be explained by stacking of the two chromophores within the dimers. This stacking results in an excitonic interaction between the two chromophores of the dimeric compounds and hence a considerable change in spectral properties. Also the change in absorption maxima from 363 nm in the monomers to 345 nm in the dimers comes as a result of this excitonic interaction.

Table 2 shows the estimated equilibrium constants of binding of 4–8 to poly(dA-dT)<sub>2</sub> as well as the ratio between the binding constant when the same drugs interacts with poly(dA-dT)<sub>2</sub> and ct-DNA. The binding constants of the monomeric indoloquinoxaline derivatives (4–6) to poly(dA-dT)<sub>2</sub> are in the order of  $10^6$ . Compound 6, which has exactly the same aromatic ring system as 4, has a slightly higher equilibrium constant. Consequently, the difference in the binding constant has to be due to the higher hydrophobicity of 6 as an effect of the additional methyl on the attached aminoethyl group. In the case of compound 5, the slight increase in DNA binding constant compared to that of compound 4 has to be ascribed to the addition of the amino-group on the aromatic ring system. As can be seen in Table 2, the binding constants of compounds (7–8) to poly(dA-dT)<sub>2</sub> are considerably higher ( $10^8$ – $10^9$ ). This is also expected since these dimeric compounds have both double the amount of functional groups and positive charges compared to those of 4–6.

A general conclusion about the drugs that can be drawn from the measurements is that they all prefer AT-DNA. As can be seen in Table 2, the preference for poly(dA-dT)<sub>2</sub> compared to ct-DNA range from 1.8 to 3.0. Since ct-DNA consists of a mixture of sites with different base composition and, thus, different binding constants, and since the number of accessible drug binding sites in ct-DNA compared to in poly(dA-dT)<sub>2</sub> is difficult to estimate, the actual values of AT-preference should not be overinterpreted. However, as a consequence of the general AT-preference among the five drugs and the magnitude of the  $K_{AT}/K_{ct-DNA}$ , there is no doubt that all of the indoloquinoxaline derivatives, like their parent compounds,<sup>36–38</sup> prefer to bind to AT-DNA (AT-regions).

Figure 3 shows the absorption spectra of 4–8 in the presence and absence of ct-DNA. As can be seen in the figure, the general trend is that the molecules show a considerable hypochromic effect and a significant red-shift of the absorption maxima upon addition of ct-DNA (dashed lines). These are common effects




**Figure 4.** Emission spectra of (a) 4, (b) 6, (c) 7, and (d) 8 in the presence (dashed lines) and absence (solid lines) of poly(dA-dT)<sub>2</sub>. Compound 5 is virtually nonfluorescent both in the presence and absence of DNA and therefore not shown. Concentration of poly(dA-dT)<sub>2</sub> is 100  $\mu\text{M}$  ([base]) and those of the monomeric and dimeric indoloquinoxaline derivatives 10 and 5  $\mu\text{M}$ , respectively. Measurements performed at room temperature in a 10 mM phosphate buffer, pH 7.5 (total  $\text{Na}^+$ -concentration 100 mM).


when drugs bind to DNA by either intercalation or groove binding. The large hypochromic effect (14–34%) and red-shift (6–19 nm) displayed by these drugs indicate intercalation rather than groove binding. (We will show more distinctive evidence of intercalation below.) The larger red-shift observed for the dimers (Figure 3d–e) can be explained by the decrease in excitonic effects as the dimers unstack upon binding to the DNA.

In Figure 4, the fluorescence spectra of 4, 6, 7, and 8 both in the presence and absence of poly(dA-dT)<sub>2</sub> are presented. As an effect of the lack of emission both with and without DNA, the result from the fluorescence measurements of compound 5 is not shown in the figure. Since the only difference in the chromophoric unit in 5 compared to that in 4 and 6 is the amino group in the 9-position, this group has to be the reason for the quenching of the emission in 5. As can be seen in Figure 4, the four fluorescent drugs all have an intrinsic emission centered at 515 nm in buffered solution (solid lines). Furthermore, upon binding to DNA they all exhibit a considerable increase in emission (dashed lines) as well as a blue-shift of more than 30 nm. Increase in emission upon binding to DNA is often considered to be a good indication of intercalation of the drug between the base pairs of the DNA, and thus, these measurements further support an intercalative mode of binding.

Figure 5 shows the flow linear dichroism (LD) spectra of the five drugs, 4–8, in the presence of ct-DNA. As can be seen from the figure, the LD of the bound drugs is purely negative. In the region where DNA has no influence on the signal (>300 nm), the LD spectra are virtually perfect mirror images of the corresponding absorption spectra of the DNA-bound drugs (for comparison see Figure 3). A negative LD proves that the angle between the DNA helix axis and the planar chromophore unit(s) of the drugs is larger than the magic angle (54.7°). When calculating the LD<sup>r</sup> of the band originating from the five drugs and subsequently the angles between the DNA helix axis and the planar chromophore unit(s), they are all in the range between 70 and 90°. This is indeed good evidence for an intercalative mode of binding for all five drugs. After determination of the binding mode by LD, SDS was added to all six DNA–drug solutions. The LD-signal of the drugs disappeared immediately, leaving only a pure DNA-LD centered around 260 nm. This



**Figure 5.** Flow linear dichroism spectra of **4** (black), **5** (red), **6** (green), **7** (blue), and **8** (cyan) in the presence of calf thymus DNA. The concentration of calf thymus DNA is 160  $\mu$ M ([base]) and those of the monomeric and dimeric indoloquinoxaline derivatives 10 and 5  $\mu$ M, respectively. Measurements performed at room temperature in a 10 mM phosphate buffer, pH 7.5 (total  $\text{Na}^+$ -concentration 100 mM).



**Figure 6.** Left: 6*H*-indolo[2,3-*b*]quinoxaline, **2**, and 2,3-dimethyl-6*H*-indolo[2,3-*b*]quinoxaline, **2a**. Right: 6-(2-dimethylaminoethyl)-6*H*-indolo[2,3-*b*]quinoxaline, **3**, and 2,3-dimethyl-6-(2-dimethylaminoethyl)-6*H*-indolo[2,3-*b*]quinoxaline, **3a**.

confirms the noncovalent nature of the DNA interaction of these drugs and indicates a fast DNA dissociation process.

The very promising antiviral effect exhibited by some of the indoloquinoxaline derivatives presented here makes them interesting in terms of their DNA binding properties. Moreover, it is important to understand the structure–activity relationship (SAR) within this set of indoloquinoxalines not only for the current derivatives and possible use of them as drugs but also for their future structural modification and further optimization.

The results obtained from absorption, fluorescence, and LD measurements all give evidence of a mode of binding where the planar aromatic parts of the indoloquinoxaline derivatives are noncovalently intercalated between the basepairs of the DNA. This mode of binding has previously been reported for the parent compounds (9-OH)-B-220<sup>39,40</sup> and is very common for positively charged planar aromatic molecules such as oxazole yellow (YO)<sup>15–17</sup> and ethidium.<sup>41</sup> For the dimers (**7–8**), this means that they are bis-intercalators with the interconnecting linker ending up in one of the grooves of the DNA. From the present measurements, we cannot conclude whether the linkers are situated in the minor or major groove, or if they are equally distributed in the two grooves. For the structurally related bis-intercalator YOYO as well as for the naturally occurring bis-intercalator echinomycin, however, the linker interconnecting the monomeric units has been found to reside in the minor groove,<sup>19,42</sup> suggesting that the linkers of our indoloquinoxaline dimers may have a minor groove preference. Also, earlier NMR studies on related compounds suggest that the side chain resides in the minor groove.<sup>36</sup> For the dimers (**7–8**), it is also important to identify the size of the DNA binding site. However, with the

data obtained in this investigation it is not possible to directly determine this number. Nevertheless, from the length of the linkers and the overall structures of the dimers we estimate the binding site size to be four and three basepairs for **7** and **8**, respectively. The smaller binding site size of **8** is further supported by the fact that using this binding site size in the calculation of the equilibrium constant (see Table 2) results in a DNA binding constant similar to that of **7**, which we expect because of the high structural resemblance of the two dimers. Finally, it should be noted that the high similarity in the results for all derivatives presented here demonstrates that the structural changes that we introduce to the indoloquinoxaline planar system only have minor effects on the mode of binding of these drugs.

The DNA-binding constant is a very important property for an antiviral drug. In the results obtained here we find that the monomeric indoloquinoxaline derivatives (**4–6**) have DNA-binding constants (AT sequence) of approximately  $10^6$ . DNA binding constants in the order of  $10^6$ , at comparable or lower ionic strengths and similar temperatures, have previously been reported for familiar intercalators such as ethidium,<sup>43</sup> YO,<sup>16</sup> actinomycin D,<sup>44</sup> daunomycin,<sup>43</sup> and  $[\text{Ru}(\text{phen})_2\text{dppz}]^{2+}$ .<sup>26</sup> These common intercalators are successfully used or have been proposed to be used, for example, as DNA stains or as antibiotics or anticancer therapeutics, and consequently, the indoloquinoxaline monomers (**4–6**) should constitute very promising DNA-binding drugs. For the dimeric indoloquinoxaline derivatives (**7–8**), we determined DNA binding constants of  $10^8$ – $10^9$  (a binding constant of **8** would be even higher if the same binding site size as that for **7** was used; see Table 2). Previously, binding constant estimates of other dimeric DNA-ligands such as YOYO ( $K \approx 10^{10}$ – $10^{12}$ ),<sup>16</sup>  $[\mu\text{-C4}(\text{cpdppz})_2(\text{phen})_4\text{Ru}_2]^{4+}$  ( $K \approx 10^9$ ),<sup>28</sup> and  $[\mu\text{-}(11,11'\text{-bidppz})(\text{phen})_4\text{Ru}_2]^{4+}$  ( $K \approx 10^{12}$ )<sup>29</sup> as well as for larger DNA-ligands such as distamycin ( $K \approx 10^9$ )<sup>43</sup> and netropsin ( $K \approx 10^9$ )<sup>43</sup> have been performed at comparable or lower ionic strengths and similar temperatures. When comparing these values to the ones obtained here for **7** and **8**, one has to remember that for the previously reported dimers the charge is two times higher and that for one of them,  $[\mu\text{-}(11,11'\text{-bidppz})(\text{phen})_4\text{Ru}_2]^{4+}$ ,<sup>29</sup> the measurements are performed at only 10 mM  $\text{Na}^+$ . Taking this into consideration, both **7** and **8** have a remarkably high binding constant to DNA, which could explain their high antiviral activity compared to the already acknowledged ganciclovir, phosphonomethanoic acid, and the B-220 compound.

In conclusion, the novel indoloquinoxaline derivatives (**4–8**) investigated here comprise a group of very promising antiviral agents that bind strongly but noncovalently to DNA in an intercalative mode. They are found to have equally high binding constants as already established DNA drugs and dyes and show a preference for AT-regions. The AT-specificity, a property shared with some of the DNA drugs and dyes mentioned above, is potentially useful for targeting viral genomes that are especially AT-rich.

## Experimental Section

**Chemistry.** Indolo[2,3-*b*]quinoxaline (**2**, Figure 6) and its derivative (**2a**, Figure 6) were easily prepared by condensation of isatin and the appropriate 1,2-phenylenediamine in glacial acetic acid according to Schunck's and Marchlewski's method.<sup>45,46</sup> Alkylation of these compounds was achieved when added to a solution containing 1-chloro-2-dimethylaminoethane hydrochloride and  $\text{K}_2\text{CO}_3$  in acetone and refluxed for 24 h. Compound **4** was obtained by dissolving the free base (**3a**, Figure 6) in acetone, and precipitation was induced by introduction of concentrated HCl. The

amino compound **5** was prepared via a two-step synthesis starting with addition of one equivalent of potassium nitrate in sulfuric acid to compound **3a** (Figure 6) to give 2,3-dimethyl-6-(2-dimethylaminoethyl)-9-nitro-6*H*-indolo[2,3-*b*]quinoxaline. Reduction of the nitro group was achieved by catalytic hydrogenation of a suspension in *N,N*-dimethylacetamide using Pd/C under hydrogen pressure (2.7 atm) for 24 h. Finally, hydrochloric acid was added to a warm solution of 9-amino-2,3-dimethyl-6-(2-dimethylaminoethyl)-6*H*-indolo[2,3-*b*]quinoxaline in water, until it reached a pH of 5. Compound **6** was prepared by refluxing compound **3a** (Figure 6) in acetonitrile with the addition of methyl iodide. The general procedure for the synthesis of compounds **7** and **8** comprised the reflux of two equivalents of compound **3** (Figure 6) and one equivalent of a suitable  $\alpha,\omega$ -dibromoalkane in acetonitrile.

Melting points were determined on a Leica Kofler hot stage and are uncorrected. NMR data were recorded on a Bruker DPX at 300.1 MHz for <sup>1</sup>H and 75.5 MHz for <sup>13</sup>C. IR spectra were acquired on a Perkin-Elmer FT-IR 1600 spectrophotometer. Elemental analyses were performed by Mikroanalytisches Laboratorium KOLBE, Germany and were within  $\pm 0.4\%$  of the calculated values.

**General Procedure for Bis-quaternary Bromides.**<sup>47</sup> 6-[2-(Dimethylamino)ethyl]-6*H*-indolo[2,3-*b*]quinoxaline was prepared according to the general procedure described for compound **3**. The free base (2 eq.) was added to a solution of the appropriate  $\alpha,\omega$ -dibromohexane (1 eq.) in acetonitrile and refluxed for 24 h. The solid thus formed was isolated by filtration.

**Bis-indolo-(2,3-*b*)quinoxaline-6*H*-(3,3;10,10-tetramethyl)-3,10-di-(3,10)-azadodecane Bromide (7).** Yield 72%; mp 260–262 °C; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>)  $\delta$  8.42 (d, 1H, *J* = 7.6 Hz), 8.28 (d, 1H, *J* = 8.3 Hz), 8.09 (d, 1H, *J* = 8.4 Hz), 7.96 (d, 1H, *J* = 8.1 Hz), 7.86–7.83 (m, 2H), 7.76–7.74 (m, 1H), 7.49 (t, 1H, *J* = 7.5 Hz), 4.98 (br t, 2H, *J* = 6.8 Hz), 3.85 (br t, 2H, *J* = 6.8 Hz), 3.53–3.47 (m, 2H), 3.25 (s, 6H), 1.78 (br s, 2H), 1.30 (br s, 2H); <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>)  $\delta$  144.8 (s), 143.6 (s), 139.8 (s), 139.6 (s), 139.0 (s), 131.6 (d), 129.3 (d), 129.2 (d), 127.4 (d), 126.6 (d), 122.5 (d), 121.8 (d), 119.1 (s), 110.7 (d), 63.2 (t), 59.2 (t), 50.8 (q), 35.0 (t), 25.4 (t), 21.7 (t). IR (neat)  $\nu$ <sub>max</sub>: 3406, 3004, 2933, 1610, 1469, 1413, 1201, 1120, 769, 752 cm<sup>-1</sup>. Anal. Calcd for (C<sub>42</sub>H<sub>48</sub>Br<sub>2</sub>N<sub>8</sub>•1/4H<sub>2</sub>O) C, H, N.

**Bis-indolo-(2,3-*b*)quinoxaline-6*H*-(3,3;7,7-tetramethyl)-3,10-di-(3,7)-azahexane Bromide (8).** Yield 68%; mp 258–260 °C; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>)  $\delta$  8.38 (d, 1H, *J* = 7.5 Hz), 8.25–8.24 (m, 1H), 8.08–8.06 (m, 1H), 7.98 (d, 1H, *J* = 8.2 Hz), 7.81–7.73 (m, 2H), 7.46 (t, 1H, *J* = 7.4 Hz), 5.03 (br t, 2H, *J* = 7.0 Hz), 3.96 (br t, 2H, *J* = 7.1 Hz), 3.72 (br t, 2H, *J* = 7.5 Hz), 3.38 (s, 6H), 2.45 (br s, 2H); <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>)  $\delta$  144.7 (s), 143.5 (s), 139.7 (s), 139.5 (s), 138.9 (s), 131.5 (d), 129.2 (d), 127.4 (d), 126.5 (d), 122.4 (d), 121.7 (d), 119.0 (s), 110.7 (d), 60.5 (t), 59.9 (t), 50.9 (q), 35.0 (t), 16.9 (t). IR (neat)  $\nu$ <sub>max</sub>: 3349, 3004, 1607, 1467, 1415, 1116, 938, 769, 752 cm<sup>-1</sup>. Anal. Calcd for (C<sub>39</sub>H<sub>42</sub>Br<sub>2</sub>N<sub>8</sub>•1/4H<sub>2</sub>O) C, H, N.

**Chemicals for DNA-Binding Studies.** Calf thymus (ct) DNA, obtained from Sigma, was dissolved in buffer and filtered twice through a 0.8  $\mu$ m Millipore filter before use. The polynucleotide, poly(dA-dT)<sub>2</sub>, was purchased from Amersham Biosciences and used as obtained. All experiments were performed in aqueous buffer (10 mM phosphate buffer at pH 7.5 and NaCl added to a total Na<sup>+</sup>-concentration of 100 mM). Sodium dodecyl sulfate (SDS) was purchased from Sigma-Aldrich. The indoloquinoxaline derivatives were synthesized as described above.

**Sample Preparation.** Samples were prepared by mixing equal volumes of indoloquinoxaline derivatives and DNA dissolved in buffer. Unless otherwise stated the sample concentrations were 10  $\mu$ M and 5  $\mu$ M of the monomeric and dimeric indoloquinoxaline derivatives, respectively, and 160  $\mu$ M ([base]) of DNA. Concentrations were determined on a Varian Cary 4B spectrophotometer. The extinction coefficients used for the DNAs were  $\epsilon_{260\text{nm}} = 6600 \text{ M}^{-1}\text{cm}^{-1}$  for ct-DNA and  $\epsilon_{262\text{nm}} = 6600 \text{ M}^{-1}\text{cm}^{-1}$  for poly(dA-dT)<sub>2</sub>. Extinction coefficient used for the indoloquinoxaline derivatives were determined as described below.

**Extinction Coefficient Determination.** The extinction coefficient of the indoloquinoxaline derivatives were determined by measuring the absorption of samples of known concentration. Samples were prepared by weighing out small amounts of the indoloquinoxaline derivatives, typically 2 mg, and dissolving them in known volumes of MQ water. Several absorption spectra of each sample were recorded on a Varian Cary 4000 spectrophotometer at room temperature and an average of the measurements was calculated. The extinction coefficients were determined as an average of between three and five independent sample preparations.

**Fluorescence.** Emission spectra were recorded at room temperature on a Xenon lamp equipped SPEX fluorolog 3 spectrofluorimeter (JY Horiba) between 365 and 750 nm using an excitation wavelength of 360 nm. Concentrations of the indoloquinoxaline derivatives were kept low in order to avoid inner filter effects.

**Flow Linear Dichroism.** Linear dichroism (LD)<sup>48</sup> is defined as the difference in absorbance of linearly polarized light parallel and perpendicular to a macroscopic orientation axis (here the flow direction):

$$LD(\lambda) = A_{\parallel}(\lambda) - A_{\perp}(\lambda) \quad (1)$$

The reduced linear dichroism LD<sup>r</sup> is calculated as

$$LD^r(\lambda) = LD(\lambda)/A_{iso} \quad (2)$$

where  $A_{iso}$  represents the absorbance of the same isotropic sample. The LD<sup>r</sup> of a single electronic transition, *i*,

$$LD_i^r = \frac{3}{2} S(3\cos^2 \alpha_i - 1) \quad (3)$$

is related to the angle  $\alpha_i$  between the *i*th transition moment direction and the molecular orientation axis, in this case the DNA helix axis. Samples with indoloquinoxaline derivatives and DNA were oriented in a Couette flow cell with an outer rotating cylinder at a shear gradient of approximately 3000 s<sup>-1</sup>. LD spectra were measured on a Jasco J-720 CD spectropolarimeter equipped with an Oxley prism to obtain linearly polarized light. All spectra were recorded between 200 and 650 nm and baseline-corrected by subtracting the spectrum recorded for the nonoriented sample.

**Equilibrium Constant Determination.** Buffered solutions containing 0, 25, 100, and 250  $\mu$ M poly(dA-dT)<sub>2</sub> as well as 10 or 5  $\mu$ M of the fluorescent monomeric or dimeric indoloquinoxaline derivatives **4**, **6**, **7**, and **8**, respectively, were prepared. Both absorption (measured on a Varian Cary 4000 spectrophotometer between 200 and 650 nm) and fluorescence spectra (for details see above) of the solutions were recorded at 22 °C. Hereafter, the solutions were diluted 10 and 100 times, and their absorption and fluorescence spectra once again recorded. The fraction of bound molecules was estimated from the measured spectra and subsequently used to calculate the equilibrium constants of the DNA binding. When calculating the equilibrium binding constants, the sizes of the DNA binding sites were assumed to be 2, 2, 4, and 3 base pairs for **4**, **6**, **7**, and **8**, respectively. The DNA binding site size for dimer **8** is assumed to be smaller due to the shorter linker between the two planar aromatic ring systems compared to that of dimer **7**.

For the virtually nonfluorescent compound **5**, competitive DNA binding with compound **6** was used to estimate the binding constant. Two buffered solutions containing 6.25  $\mu$ M poly(dA-dT)<sub>2</sub> as well as 2.5 or 3.75  $\mu$ M of **6** were prepared. Also, two solutions containing the same amount of poly(dA-dT)<sub>2</sub> and half the amount of **6** compared to the two above as well as 1.25 or 1.875  $\mu$ M of **5**, respectively, were prepared. The fluorescence of DNA-bound **6** from the four samples was measured. The changes in emission as an effect of compound **5** competing with compound **6** about the DNA binding sites in combination with the previously determined DNA binding constant of **6** were then used to estimate the equilibrium binding constant of the nonfluorescent **5** when binding to DNA.

The difference in the equilibrium constant of binding of the various indoloquinoxaline derivatives to the two forms of DNA, ct-DNA and poly(dA-dT)<sub>2</sub>, was measured using flow LD. The LD of each indoloquinoxaline derivative (5 and 10  $\mu$ M of the dimeric and monomeric ones, respectively) bound to ct-DNA (160  $\mu$ M) was recorded and compared to the LD of the same molecule when mixed into a solution of a combination of ct-DNA (80  $\mu$ M) and poly(dA-dT)<sub>2</sub> (80  $\mu$ M). As a result of the short polynucleotide strands (699 base pairs), the measured LD of the indoloquinoxaline derivatives bound to poly(dA-dT)<sub>2</sub> (160  $\mu$ M) has virtually no intensity.

**Supporting Information Available:** Details of the preparation of compounds **3**, **3a**, and **4–8** as well as <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of compounds **3**, **3a**, and **4–8**; elemental analysis results of target compounds **4–8**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## References

- Goodwin, S.; Smith, A. F.; Horning, E. C. Alkaloids of *Ochrosia elliptica* Labill. *J. Am. Chem. Soc.* **1959**, *81*, 1903–1908.
- Juret, P.; Tanguy, A.; Girard, A.; Letalaer, J. Y.; Abbatucci, J. S.; Datxuong, N.; LePecq, J. B.; Paoletti, C. Preliminary trial of 9-hydroxy-2-methyl ellipticinium (Nsc 264–137) in advanced human cancers. *Eur. J. Cancer.* **1978**, *14*, 205–206.
- Bergman, J.; Åkerfeldt, S. G. Substituted Indoloquinoxalines. Patent WO 87/04436, 1987.
- Wamberg, M. C.; Hassan, A. A.; Bond, A. D.; Pedersen, E. B. Intercalating nucleic acids (INAs) containing insertions of 6H-indolo[2,3-*b*]quinoxaline. *Tetrahedron* **2006**, *62*, 11187–11199.
- Harmenberg, J.; Wahren, B.; Bergman, J.; Åkerfeldt, S.; Lundblad, L. Antiherpesvirus activity and mechanism of action of indolo-(2,3-*b*)quinoxaline and analogs. *Antimicrob. Agents Chemother.* **1988**, *32*, 1720–1724.
- Harmenberg, J.; Åkesson-Johansson, A.; Gräslund, A.; Malmfors, T.; Bergman, J.; Wahren, B.; Åkerfeldt, S.; Lundblad, L.; Cox, S. The mechanism of action of the anti-herpes virus compound 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-(2,3-*b*)quinoxaline. *Antiviral Res.* **1991**, *15*, 193–204.
- Björklund, U.; Engqvist, R.; Kihlström, I.; Gerdin, B.; Bergman, J. Alkyl Substituted Indoloquinoxalines. Patent WO 2005/123741, 2005.
- Crenshaw, J. M.; Graves, D. E.; Denny, W. A. Interactions of acridine antitumor agents with DNA: binding-energies and groove preferences. *Biochemistry.* **1995**, *34*, 13682–13687.
- Petty, J. T.; Bordelon, J. A.; Robertson, M. E. 2000. Thermodynamic characterization of the association of cyanine dyes with DNA. *J. Phys. Chem. B* **2000**, *104*, 7221–7227.
- Frodl, A.; Herebian, D.; Sheldrick, W. S. Coligand tuning of the DNA binding properties of bioorganometallic (eta(6)-arene)ruthenium(II) complexes of the type  $[(\eta_6\text{-arene})\text{Ru}(\text{amino acid})(\text{dppz})]^{n+}$  (dppz = dipyrido[3,2-*a*: 2',3'-*c*]phenazine),  $n=1–3$ . *J. Chem. Soc., Dalton Trans.* **2002**, 3664–3673.
- White, E. W.; Tanious, F.; Ismail, M. A.; Reszka, A. P.; Neidle, S.; Boykin, D. W.; Wilson, W. D. Structure-specific recognition of quadruplex DNA by organic cations: Influence of shape, substituents and charge. *Biophys. Chem.* **2007**, *126*, 140–153.
- Capelle, N.; Barbet, J.; Dessen, P.; Blanquet, S.; Roques, B. P.; Lepecq, J. B. Deoxyribonucleic-acid bifunctional intercalators: kinetic investigation of the binding of several acridine dimers to deoxyribonucleic-acid. *Biochemistry.* **1979**, *18*, 3354–3362.
- Gallego, J.; Reid, B. R. Solution structure and dynamics of a complex between DNA and the antitumor bisnaphthalimide LU-79553: Intercalated ring flipping on the millisecond time scale. *Biochemistry.* **1999**, *38*, 15104–15115.
- Carlsson, C.; Larsson, A.; Jonsson, M.; Albinsson, B.; Nordén, B. Optical and photophysical properties of the oxazole yellow DNA probes Yo and YoYo. *J. Phys. Chem.* **1994**, *98*, 10313–10321.
- Larsson, A.; Carlsson, C.; Jonsson, M.; Albinsson, N. Characterization of the binding of the fluorescent dyes Yo and YoYo to DNA by polarized-light spectroscopy. *J. Am. Chem. Soc.* **1994**, *116*, 8459–8465.
- Glazer, A. N.; Rye, H. S. Stable dye-DNA intercalation complexes as reagents for high-sensitivity fluorescence detection. *Nature.* **1992**, *359*, 859–861.
- Rye, H. S.; Yue, S.; Wemmer, D. E.; Quesada, M. A.; Haugland, R. P.; Mathies, R. A.; Glazer, A. N. Stable fluorescent complexes of double-stranded DNA with bis- intercalating asymmetric cyanine dyes: properties and applications. *Nucleic Acids Res.* **1992**, *20*, 2803–2812.
- Rye, H. S.; Yue, S.; Quesada, M. A.; Haugland, R. P.; Mathies, R. A.; Glazer, A. N. Picogram detection of stable dye DNA intercalation complexes with 2-color laser-excited confocal fluorescence gel scanner. *Methods Enzymol.* **1993**, *217*, 414–431.
- Johansen, F.; Jacobsen, J. P. H-1 NMR studies of the bis-intercalation of a homodimeric oxazole yellow dye in DNA oligonucleotides. *J. Biomol. Struct. Dyn.* **1998**, *16*, 205–222.
- Spielmann, H. P.; Wemmer, D. E.; Jacobsen, J. P. Solution structure of a DNA complex with the fluorescent bis-intercalator toto determined by NMR-spectroscopy. *Biochemistry* **1995**, *34*, 8542–8553.
- Hu, G. G.; Shui, X. Q.; Leng, F. F.; Priebe, W.; Chaires, J. B.; Williams, L. D. Structure of a DNA-bisdaunomycin complex. *Biochemistry* **1997**, *36*, 5940–5946.
- Robinson, H.; Priebe, W.; Chaires, J. B.; Wang, A. H. J. Binding of two novel bisdaunorubicins to DNA studied by NMR spectroscopy. *Biochemistry* **1997**, *36*, 8663–8670.
- Leng, F. F.; Priebe, W.; Chaires, J. B. Ultratight DNA binding of a new bisintercalating anthracycline antibiotic. *Biochemistry* **1998**, *37*, 1743–1753.
- Friedman, A. E.; Kumar, C. V.; Turro, N. J.; Barton, J. K. Luminescence of ruthenium(II) polypyridyls: evidence for intercalative binding to Z-DNA. *Nucleic Acids Res.* **1991**, *19*, 2595–2602.
- Lincoln, P.; Broo, A.; Nordén, B. Diastereomeric DNA-binding geometries of intercalated ruthenium(II) trischelates probed by linear dichroism:  $[\text{Ru}(\text{phen})\text{dppz}]^{2+}$  and  $[\text{Ru}(\text{phen})_2\text{dppz}]^{2+}$ . *J. Am. Chem. Soc.* **1996**, *118*, 2644–2653.
- Haq, I.; Lincoln, P.; Suh, D. C.; Nordén, B.; Chowdhry, B. Z.; Chaires, J. B. Interaction of  $\Delta$ - $[\text{Ru}(\text{phen})_2\text{dppz}]^{2+}$  and  $\lambda$ - $[\text{Ru}(\text{phen})_2\text{dppz}]^{2+}$  with DNA: a calorimetric and equilibrium binding study. *J. Am. Chem. Soc.* **1995**, *117*, 4788–4796.
- Önfelt, B.; Lincoln, P.; Nordén, B. A molecular staple for DNA: threading bis-intercalating  $[\text{Ru}(\text{phen})_2\text{dppz}]^{2+}$  Dimer. *J. Am. Chem. Soc.* **1999**, *121*, 10846–10847.
- Önfelt, B.; Lincoln, P.; Nordén, B. Enantioselective DNA threading dynamics by phenazine-linked  $[\text{Ru}(\text{phen})_2\text{dppz}]^{2+}$  dimers. *J. Am. Chem. Soc.* **2001**, *123*, 3630–3637.
- Lincoln, P.; Nordén, B. Binuclear ruthenium(II)phenanthroline compounds with extreme binding affinity for DNA. *Chem. Communication.* **1996**, *214*, 5–2146.
- Wilhelmsson, L. M.; Westerlund, F.; Lincoln, P.; Nordén, B. DNA-binding of semirigid binuclear ruthenium complex  $\Delta, \Delta$ - $[\mu-(11,11'\text{-bidppz})(\text{phen})_4\text{Ru}-2]^{4+}$ : Extremely slow intercalation kinetics. *J. Am. Chem. Soc.* **2002**, *124*, 12092–12093.
- Wilhelmsson, L. M.; Esbjörner, E. K.; Westerlund, F.; Nordén, B.; Lincoln, P. Meso stereoisomer as a probe of enantioselective threading intercalation of semirigid ruthenium complex  $\mu-(11,11'\text{-bidppz})(\text{phen})_4\text{Ru}-2^{4+}$ . *J. Phys. Chem. B* **2003**, *107*, 11784–11793.
- Nordell, P.; Westerlund, F.; Wilhelmsson, L. M.; Nordén, B.; Lincoln, P. Kinetic recognition of AT-rich DNA by ruthenium complexes. *Angew. Chem., Int. Ed.* **2007**, *46*, 2203–2206.
- Karlsson, H. J.; Bergqvist, M. H.; Lincoln, P.; Westman, G. Syntheses and DNA-binding studies of a series of unsymmetrical cyanine dyes: structural influence on the degree of minor groove binding to natural DNA. *Bioorg. Med. Chem.* **2004**, *12*, 2369–2384.
- Hommel, M.; Engqvist, R.; Söderberg-Naucler, C.; Bergman, J. Novel Compounds and Use Thereof. Patent WO 2007/084073 A1, 2007.
- Przyjazna, B.; Kucybala, Z.; Paczkowski, J. P. Development of new dyeing photoinitiators based on 6H-indolo[2,3-*b*]quinoxaline skeleton. *Polymer* **2004**, *45*, 2559–2566.
- Behravan, G.; Leijon, M.; Sehlstedt, U.; Nordén, B.; Vallberg, H.; Bergman, J.; Gräslund, A. The Interaction of ellipticine derivatives with nucleic-acids studied by optical and H-1-NMR spectroscopy: effect of size of the heterocyclic ring. *Biopolymers* **1994**, *34*, 599–609.
- Zegar, I.; Gräslund, A.; Bergman, J.; Eriksson, M.; Nordén, B. Interaction of ellipticine and an indolo[2,3-*b*]quinoxaline derivative with DNA and synthetic polynucleotides. *Chem.-Biol. Interact.* **1989**, *72*, 277–293.
- Patel, N.; Bergman, J.; Gräslund, A. H-1-NMR studies of the interaction between a self-complementary deoxyoligonucleotide duplex and indolo[2,3-*b*]quinoxaline derivatives active against herpes-virus. *Eur. J. Biochem.* **1991**, *197*, 597–604.
- Sehlstedt, U.; Aich, P.; Bergman, J.; Vallberg, H.; Nordén, B.; Gräslund, A. Interactions of the antiviral quinoxaline derivative 9-OH-B220 {2,3-dimethyl-6-(dimethylaminoethyl)-9-hydroxy-6H-indolo[2,3-*b*]quinoxaline} with duplex and triplex forms of synthetic DNA and RNA. *J. Mol. Biol.* **1998**, *278*, 31–56.
- Sandström, K.; Wärmländer, S.; Bergman, J.; Engqvist, R.; Leijon, M.; Gräslund, A. The influence of intercalator binding on DNA triplex stability: correlation with effects on A-tract duplex structure. *J. Mol. Recognit.* **2004**, *17*, 277–285.
- Fuller, W.; Waring, M. J. A molecular model for the interaction of ethidium bromide with deoxyribonucleic acid. *Ber. Bunsen-Ges. Phys. Chem.* **1964**, *68*, 805–808.

(42) Gilbert, D. E.; Feigon, J. (1991). The DNA-sequence at echinomycin binding-sites determines the structural-changes induced by drug-binding: NMR-studies of echinomycin binding to [d(ACG-TACGT)]<sub>2</sub> and [d(TCGATCGA)]<sub>2</sub>. *Biochemistry*. **1991**, *30*, 2483–2494.

(43) Breslauer, K. J.; Remeta, D. P.; Chou, W. Y.; Ferrante, R.; Curry, J.; Zaunczkowski, D.; Snyder, J. G.; Marky, L. A. Enthalpy entropy compensations in drug DNA-binding studies. *Proc. Natl. Acad. Sci. U.S.A.* **1987**, *84*, 8922–8926.

(44) Marky, L. A.; Snyder, J. G.; Remeta, D. P.; Breslauer, K. J. Thermodynamics of drug-DNA interactions. *J. Biomol. Struct. Dyn.* **1983**, *1*, 487–507.

(45) Schunk, E.; Marchlewski, L. Zur Kenntniss der rothen Isomeren des Indigotins und über einige Derivate des Isatins. *Chem. Ber.* **1895**, *28*, 2525–2531.

(46) Buraczewski, J.; Marchlewski, L. Zur Kenntniss des Isatins. *Chem. Ber.* **1901**, *34*, 4008–4015.

(47) Bergman, J. Formation of N-N bonds by thermolysis of 5-(2-dimethylaminoethyl)-5H-indolo[2,3-*b*]quinoxaline. *Tetrahedron Lett.* **1989**, *30*, 1837–1840.

(48) Nordén, B.; Kubista, M.; Kurucsev, T. Linear dichroism spectroscopy of nucleic-acids. *Q. Rev. Biophys.* **1992**, *25*, 51–170.

JM800787B